MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the thirteen brokerages that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $79.00.
Several analysts recently commented on the stock. HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of MoonLake Immunotherapeutics in a report on Monday. Wedbush reaffirmed an “outperform” rating and issued a $92.00 price target on shares of MoonLake Immunotherapeutics in a research note on Wednesday, March 13th. The Goldman Sachs Group began coverage on MoonLake Immunotherapeutics in a research report on Tuesday, April 2nd. They set a “neutral” rating and a $62.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 target price on shares of MoonLake Immunotherapeutics in a research report on Monday, June 10th. Finally, Oppenheimer initiated coverage on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 25th. They issued an “outperform” rating and a $104.00 target price for the company.
View Our Latest Stock Report on MoonLake Immunotherapeutics
MoonLake Immunotherapeutics Price Performance
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) last announced its quarterly earnings data on Sunday, May 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, equities research analysts forecast that MoonLake Immunotherapeutics will post -1.21 EPS for the current fiscal year.
Hedge Funds Weigh In On MoonLake Immunotherapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Quarry LP bought a new position in MoonLake Immunotherapeutics during the fourth quarter worth about $51,000. Barclays PLC acquired a new stake in MoonLake Immunotherapeutics in the 3rd quarter valued at $189,000. Stratos Wealth Partners LTD. acquired a new position in MoonLake Immunotherapeutics during the fourth quarter worth $202,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in MoonLake Immunotherapeutics during the fourth quarter worth $217,000. Finally, Bellevue Group AG bought a new position in shares of MoonLake Immunotherapeutics during the first quarter valued at $221,000. 93.85% of the stock is owned by institutional investors.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Further Reading
- Five stocks we like better than MoonLake Immunotherapeutics
- How to buy stock: A step-by-step guide for beginners
- RXO Shares Surge Following New Acquisition Deal
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- What is the Australian Securities Exchange (ASX)
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.